k8凯发(中国)天生赢家·一触即发

IMPACT Therapeutics today announced that the preliminary clinical results for a phase 1b/2 study investigating the PARP inhibitor Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors and extensive stage small cell lung cancer has been presented as a poster at ASCO2022. ASCO2022 is taking place Jun 3 to 7 in Chicago, US. The data published this time was from the data of dose escalation part in patients with solid tumors and dose expansion part in patients with extensive stage small cell lung cancer of the study.

Highlights of the poster/abstract (refer to ASCO2022 for more details)

Abstract Number: 3102

Abstract Title: A study of senaparib in Combination with Temozolomide for the Treatment of Patients with Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Session Date/Time/locations: 6/5/2022, 8:00 AM-11:00 AM CDT, Hall A

Poster Board: #94

The study results presented at this meeting include the safety, tolerability and the preliminary efficacy of senaparib in combination with TMZ in patients with advance solid tumors during the dose escalation part, and preliminary efficacy and safety in the patients with extensive stage small cell lung cancer during the dose expansion part. A total of 14 patients were enrolled for dose escalation and the dose escalation has been completed in all planned dose levels. The MTD and RP2D were determined as senaparib 80 mg once daily plus temozolomide 20 mg once daily. The ORR was observed in 4 of 12 (33.3%) evalsuable patients, including 3 confirmed PR. The DCR was 83.3%. median DOR was 3.6 months. Two patients remain on treatment for more than 1 year. A total of 14 patients with extensive stage small cell lung cancer post first-line treatment were enrolled as of the date. The ORR was observed in 3 of 7 (42.9%) evalsuable patients, including 2 confirmed PR who were still on treatment. All AEs reported were manageable. The recruitment for part 2 is still ongoing.

About IMPACT Therapeutics

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received US IND Clearance from FDA and China IND application from NMPA and the first patient has been dosed in the US. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA.